Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of science and Technology, Wuhan, Hubei, China.
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of science and Technology, Wuhan, Hubei, China.
Blood Rev. 2024 Nov;68:101237. doi: 10.1016/j.blre.2024.101237. Epub 2024 Sep 5.
Liquid biopsy, particularly circulating tumor DNA (ctDNA), has drawn a lot of attention as a non- or minimal-invasive detection approach for clinical applications in patients with cancer. Many hematological malignancies are well suited for serial and repeated ctDNA surveillance due to relatively high ctDNA concentrations and high loads of tumor-specific genetic and epigenetic abnormalities. Progress of detecting technology in recent years has improved sensitivity and specificity significantly, thus broadening and strengthening the potential utilities of ctDNA including early diagnosis, prognosis estimation, treatment response evaluation, minimal residual disease monitoring, targeted therapy selection, and immunotherapy surveillance. This manuscript reviews the detection methodologies, clinical application and future challenges of ctDNA in hematological malignancies, especially for lymphomas, myeloma and leukemias.
液体活检，特别是循环肿瘤 DNA（ctDNA），作为一种非侵入性或微创的检测方法，在癌症患者的临床应用中引起了广泛关注。许多血液系统恶性肿瘤非常适合进行连续和重复的 ctDNA 监测，因为其 ctDNA 浓度相对较高，并且具有大量肿瘤特异性的遗传和表观遗传异常。近年来检测技术的进步显著提高了灵敏度和特异性，从而拓宽和加强了 ctDNA 的潜在应用，包括早期诊断、预后评估、治疗反应评估、微小残留病监测、靶向治疗选择和免疫治疗监测。本文综述了 ctDNA 在血液系统恶性肿瘤，特别是淋巴瘤、骨髓瘤和白血病中的检测方法、临床应用和未来挑战。
